Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

How BioMarin Beat Expectations in Q3

TheMotleyFool

0 0

2020 is looking like a year to forget for BioMarin Pharmaceutical (NASDAQ: BMRN). The decision by the Food and Drug Administration (FDA) to not approve Roctavian (valoctocogene roxaparvovec) in treating severe hemophilia A rocked the company and its share price.

BioMarin had an opportunity to give investors some good news when the company announced its third-quarter results after the market closed on Thursday. Here are the highlights from BioMarin's Q3 update.

Image source: Getty Images.

Source Fool.com

Like: 0

BMRN

Share